Obiective
Evaluate real-world progression-free survival
Operator de date
Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Categorii de date utilizate
Données d’identification (sans donnée nominative) / Données de santé
Origine de données utilisées
Soins
Institut de Cancérologie de l'Ouest (Nantes et Angers)
Populația care face obiectul cercetării sau al prelucrării datelor
Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib • Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) • Patients who received at least one dose of the treatment with sotorasib as part of the French Early Access Program (ATU program) • Patients who were informed about the study and do not object for their data to be collected • Age > 18 years
Temei juridic
Intérêt public
Destinatari interni și externi ai datelor
IFCT
Data de începere a cercetării
24/03/2022
Perioada de păstrare a datelor
Durée conforme à la réglementation